Theodore Pincus to Arthritis, Rheumatoid
This is a "connection" page, showing publications Theodore Pincus has written about Arthritis, Rheumatoid.
Connection Strength
28.214
-
Should Quantitative Measures and Management of Rheumatoid Arthritis Include More Than Control of Inflammatory Activity? J Rheumatol. 2022 Mar; 49(3):336-338.
Score: 0.594
-
Comment on: 'It can't be zero!' Difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study. Rheumatology (Oxford). 2021 01 05; 60(1):e28-e29.
Score: 0.563
-
Multidimensional Health Assessment Questionnaire as an Effective Tool to Screen for Depression in Routine Rheumatology Care. Arthritis Care Res (Hoboken). 2021 01; 73(1):120-129.
Score: 0.562
-
Long-term Glucocorticoid Use in Rheumatoid Arthritis. J Rheumatol. 2021 08; 48(8):1342.
Score: 0.554
-
Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):7-17.
Score: 0.517
-
Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. Arthritis Rheumatol. 2019 08; 71(8):1276-1284.
Score: 0.507
-
Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis. J Rheumatol. 2019 01; 46(1):27-30.
Score: 0.482
-
Assessment of pain and other patient symptoms in routine clinical care as quantitative, standardised, "scientific" data. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):13-20.
Score: 0.449
-
Pain and other self-report scores in patients with osteoarthritis indicate generally similar disease burden to patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):88-93.
Score: 0.449
-
Limited Value of the Multi-Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis: Comment on the Article by Fleischmann et al and Accompanying Editorial by Davis. Arthritis Rheumatol. 2017 04; 69(4):866-867.
Score: 0.431
-
Electronic multidimensional health assessment questionnaire (eMDHAQ): past, present and future of a proposed single data management system for clinical care, research, quality improvement, and monitoring of long-term outcomes. Clin Exp Rheumatol. 2016 Sep-Oct; 34(5 Suppl 101):S17-S33.
Score: 0.420
-
Electronic eRAPID3 (Routine Assessment of Patient Index Data): opportunities and complexities. Clin Exp Rheumatol. 2016 Sep-Oct; 34(5 Suppl 101):S49-S53.
Score: 0.420
-
Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. J Rheumatol. 2016 07; 43(7):1285-91.
Score: 0.406
-
Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? Clin Exp Rheumatol. 2015 Sep-Oct; 33(5 Suppl 93):S82-93.
Score: 0.392
-
Rheumatoid arthritis: Predicting mortality in RA: the quest for useful information. Nat Rev Rheumatol. 2015 Sep; 11(9):507-9.
Score: 0.384
-
Are patient self-report questionnaires as "scientific" as biomarkers in "treat-to-target" and prognosis in rheumatoid arthritis? Curr Pharm Des. 2015; 21(2):241-56.
Score: 0.371
-
Circadian use of glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation. 2015; 22(1-2):33-9.
Score: 0.363
-
Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis. Neuroimmunomodulation. 2015; 22(1-2):46-50.
Score: 0.363
-
The past versus the present, 1980-2004: reduction of mean initial low-dose, long-term glucocorticoid therapy in rheumatoid arthritis from 10.3 to 3.6 mg/day, concomitant with early methotrexate, with long-term effectiveness and safety of less than 5 mg/day. Neuroimmunomodulation. 2015; 22(1-2):89-103.
Score: 0.363
-
Is a patient questionnaire without a joint examination as undesirable as a joint examination without a patient questionnaire? J Rheumatol. 2014 Apr; 41(4):619-21.
Score: 0.352
-
Assessing remission in rheumatoid arthritis on the basis of patient reported outcomes--advantages of using RAPID3/MDHAQ in routine care. Bull Hosp Jt Dis (2013). 2014; 72(2):136-41.
Score: 0.346
-
Documenting the value of care for rheumatoid arthritis, analogous to hypertension, diabetes, and hyperlipidemia: is control of individual patient self-report measures of global estimate and physical function more valuable than laboratory tests, radiographs, indices, or remission criteria? J Rheumatol. 2013 Sep; 40(9):1469-74.
Score: 0.338
-
Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken). 2013 May; 65(5):729-36.
Score: 0.330
-
Patient self-report RADAI (Rheumatoid Arthritis Disease Activity Index) joint counts on an MDHAQ (Multidimensional Health Assessment Questionnaire) in usual care of consecutive patients with rheumatic diseases other than rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Feb; 65(2):288-93.
Score: 0.325
-
Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort. J Rheumatol. 2013 Apr; 40(4):386-93.
Score: 0.325
-
RAPID3, an index of only 3 patient self-report core data set measures, but not ESR, recognizes incomplete responses to methotrexate in usual care of patients with rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71(2):117-20.
Score: 0.323
-
Update on methotrexate as the anchor drug for rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S9-19.
Score: 0.323
-
Efficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritis. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S20-8.
Score: 0.323
-
Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis (2013). 2013; 71 Suppl 1:S33-40.
Score: 0.323
-
Treat-to-target: not as simple as it appears. Clin Exp Rheumatol. 2012 Jul-Aug; 30(4 Suppl 73):S10-20.
Score: 0.318
-
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis. Ann Intern Med. 2012 Aug 21; 157(4):299; author reply 300.
Score: 0.315
-
Importance of patient history and physical examination in rheumatoid arthritis compared to other chronic diseases: results of a physician survey. Arthritis Care Res (Hoboken). 2012 Aug; 64(8):1250-5.
Score: 0.314
-
An evidence-based medical visit for patients with rheumatoid arthritis based on standard, quantitative scientific data from a patient MDHAQ and physician report. Bull NYU Hosp Jt Dis. 2012; 70(2):73-94.
Score: 0.301
-
Effective initial and long-term prednisone in doses of less than 5 mg/day to treat rheumatoid arthritis--documentation using a patient self-report Multidimensional Health Assessment Questionnaire (MDHAQ). Bull NYU Hosp Jt Dis. 2012; 70 Suppl 1:14-20.
Score: 0.301
-
Pragmatic and scientific advantages of MDHAQ/ RAPID3 completion by all patients at all visits in routine clinical care. Bull NYU Hosp Jt Dis. 2012; 70 Suppl 1:30-6.
Score: 0.301
-
Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials. J Rheumatol. 2011 Dec; 38(12):2565-71.
Score: 0.299
-
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1142-9.
Score: 0.293
-
Differences in treat-to-target in patients with rheumatoid arthritis versus hypertension and diabetes--consequences for clinical care. Bull NYU Hosp Jt Dis. 2011; 69(2):104-10.
Score: 0.281
-
In the clinic. Rheumatoid arthritis. Ann Intern Med. 2010 Jul 06; 153(1):ITC1-1-ITC1-15; quiz ITC1-16.
Score: 0.272
-
Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2010 Sep; 49(9):1795-6; author reply 1796-7.
Score: 0.269
-
RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds. Arthritis Care Res (Hoboken). 2010 Feb; 62(2):181-9.
Score: 0.264
-
Complexities in assessment of rheumatoid arthritis: absence of a single gold standard measure. Rheum Dis Clin North Am. 2009 Nov; 35(4):687-97, v.
Score: 0.259
-
A biopsychosocial model to complement a biomedical model: patient questionnaire data and socioeconomic status usually are more significant than laboratory tests and imaging studies in prognosis of rheumatoid arthritis. Rheum Dis Clin North Am. 2009 Nov; 35(4):699-712, v.
Score: 0.259
-
Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheum Dis Clin North Am. 2009 Nov; 35(4):713-22, v-vi.
Score: 0.259
-
Radiographic measures to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am. 2009 Nov; 35(4):723-9, vi.
Score: 0.259
-
Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am. 2009 Nov; 35(4):731-4, vi-vii.
Score: 0.259
-
Patient questionnaires in rheumatoid arthritis: advantages and limitations as a quantitative, standardized scientific medical history. Rheum Dis Clin North Am. 2009 Nov; 35(4):735-43, vii.
Score: 0.259
-
RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009 Nov; 35(4):773-8, viii.
Score: 0.259
-
A Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from a patient and a health professional in a uniform "scientific" format. Rheum Dis Clin North Am. 2009 Nov; 35(4):843-50, xi.
Score: 0.259
-
Criterion contamination of depression scales in patients with rheumatoid arthritis: the need for interpretation of patient questionnaires (as all clinical measures) in the context of all information about the patient. Rheum Dis Clin North Am. 2009 Nov; 35(4):861-4, xi-xii.
Score: 0.259
-
Management of associated rheumatoid arthritis and fibromyalgia. J Rheumatol. 2009 Sep; 36(9):2123-4; discussion 2124-5.
Score: 0.256
-
Rheumatoid arthritis: strategy more important than agent. Lancet. 2009 Aug 08; 374(9688):430-2.
Score: 0.255
-
Is a self-report RAPID3 score a reasonable alternative to a DAS28 in usual clinical care? J Clin Rheumatol. 2009 Aug; 15(5):215-7.
Score: 0.255
-
Quantitative clinical rheumatology: why is a test for anti-CCP antibodies included in most routine care for rheumatoid arthritis while a HAQ/MDHAQ remains largely a research tool? J Rheumatol. 2009 Aug; 36(8):1563-4.
Score: 0.255
-
Declines in erythrocyte sedimentation rates in patients with rheumatoid arthritis over the second half of the 20th century. J Rheumatol. 2009 Aug; 36(8):1596-9.
Score: 0.253
-
Quantitative clinical rheumatology: "keep it simple, stupid": MDHAQ function, pain, global, and RAPID3 quantitative scores to improve and document the quality of rheumatologic care. J Rheumatol. 2009 Jun; 36(6):1099-100.
Score: 0.252
-
Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol. 2009 Jul; 36(7):1387-90.
Score: 0.250
-
Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care? Bull NYU Hosp Jt Dis. 2009; 67(3):254-66.
Score: 0.245
-
RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008 Nov; 35(11):2136-47.
Score: 0.240
-
Are excellent systematic reviews of clinical trials useful for patient care? Nat Clin Pract Rheumatol. 2008 Jun; 4(6):294-5.
Score: 0.234
-
Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol. 2008; 18(3):228-39.
Score: 0.233
-
Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol. 2008 Apr; 35(4):603-9.
Score: 0.231
-
Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008; 66(3):216-23.
Score: 0.228
-
Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol. 2008 Feb; 35(2):201-5.
Score: 0.226
-
A three-page Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from patients and health professionals in standard clinical care and clinical research. Best Pract Res Clin Rheumatol. 2007 Aug; 21(4):677-85.
Score: 0.222
-
A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol. 2007 Aug; 21(4):755-87.
Score: 0.222
-
A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). Best Pract Res Clin Rheumatol. 2007 Aug; 21(4):789-804.
Score: 0.222
-
N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? J Rheumatol. 2007 Feb; 34(2):250-2.
Score: 0.214
-
Patient questionnaires and formal education as more significant prognostic markers than radiographs or laboratory tests for rheumatoid arthritis mortality--limitations of a biomedical model to predict long-term outcomes. Bull NYU Hosp Jt Dis. 2007; 65 Suppl 1:S29-36.
Score: 0.213
-
Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials. J Rheumatol. 2006 Dec; 33(12):2372-5.
Score: 0.212
-
Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population. Arthritis Rheum. 2006 Oct; 54(10):3113-8.
Score: 0.209
-
The DAS is the most specific measure, but a patient questionnaire is the most informative measure to assess rheumatoid arthritis. J Rheumatol. 2006 May; 33(5):834-7.
Score: 0.203
-
Advantages and limitations of quantitative measures to assess rheumatoid arthritis: joint counts, radiographs, laboratory tests, and patient questionnaires. Bull NYU Hosp Jt Dis. 2006; 64(1-2):32-9.
Score: 0.199
-
Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al. Arthritis Rheum. 2005 Dec; 52(12):4044-5; author reply 4045-7.
Score: 0.198
-
A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol. 2005 Dec; 32(12):2410-5.
Score: 0.198
-
Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol. 2005 Jul; 32(7):1261-6.
Score: 0.192
-
Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum. 2005 Apr; 52(4):1031-6.
Score: 0.189
-
Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum. 2005 Apr; 52(4):1009-19.
Score: 0.189
-
Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. Rheum Dis Clin North Am. 2004 Nov; 30(4):725-51, vi.
Score: 0.183
-
Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum. 2004 Jun; 50(6):1734-9.
Score: 0.178
-
Add-on or step-up trials in rheumatoid arthritis: comment on the article by Boers. Arthritis Rheum. 2004 Apr; 50(4):1351; author reply 1351-2.
Score: 0.176
-
Patient questionnaires and formal education level as prospective predictors of mortality over 10 years in 97% of 1416 patients with rheumatoid arthritis from 15 United States private practices. J Rheumatol. 2004 Feb; 31(2):229-34.
Score: 0.174
-
Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol. 2003 Oct; 17(5):753-81.
Score: 0.170
-
Guidelines for monitoring of methotrexate therapy: "evidence-based medicine" outside of clinical trials. Arthritis Rheum. 2003 Oct; 48(10):2706-9.
Score: 0.170
-
Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. J Rheumatol. 2003 Jun; 30(6):1138-46.
Score: 0.166
-
Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum. 2003 Feb; 48(2):313-8.
Score: 0.162
-
Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol. 2002 Dec; 29(12):2521-4.
Score: 0.161
-
Satisfaction With a Virtual Learning Collaborative Aimed at Implementing Treat-to-Target in Rheumatoid Arthritis. J Clin Rheumatol. 2022 Aug 01; 28(5):265-269.
Score: 0.155
-
Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum. 2002 Apr; 46(4):851-4.
Score: 0.153
-
Implementing a Treat-to-Target Approach for Rheumatoid Arthritis During the COVID-19 Pandemic: Results of a Virtual Learning Collaborative Program. Arthritis Care Res (Hoboken). 2022 04; 74(4):572-578.
Score: 0.152
-
Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful?. Ann Intern Med. 2002 Jan 01; 136(1):76-8.
Score: 0.151
-
Functional Status Measures and Indices in Rheumatoid Arthritis: Comment on the Articles by Barber et al and England et al. Arthritis Care Res (Hoboken). 2020 08; 72(8):1185-1186.
Score: 0.136
-
Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. Arthritis Rheumatol. 2017 07; 69(7):1374-1380.
Score: 0.110
-
Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry. J Rheumatol. 2015 Oct; 42(10):1781-5.
Score: 0.097
-
GUEPARD treat-to-target strategy is significantly more efficacious than ESPOIR routine care in early rheumatoid arthritis according to patient-reported outcomes and physician global estimate. Rheumatology (Oxford). 2013 Oct; 52(10):1890-7.
Score: 0.084
-
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011 Mar; 70(3):404-13.
Score: 0.071
-
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar; 63(3):573-86.
Score: 0.071
-
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep; 69(9):1580-8.
Score: 0.069
-
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep; 62(9):2569-81.
Score: 0.069
-
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010 Sep; 62(9):2582-91.
Score: 0.069
-
Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J Rheumatol. 2010 Aug 01; 37(8):1633-8.
Score: 0.067
-
Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010; 12(2):R42.
Score: 0.066
-
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2009 Nov 15; 61(11):1580-5.
Score: 0.065
-
Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum. 2009 Jul; 60(7):1906-14.
Score: 0.063
-
Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009; 11(1):R7.
Score: 0.061
-
Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries. Arthritis Rheum. 2008 Sep; 58(9):2642-51.
Score: 0.060
-
Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum. 2008 Sep; 58(9):2662-9.
Score: 0.060
-
Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008 Jul; 58(7):2105-12.
Score: 0.059
-
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008; 10(2):R30.
Score: 0.058
-
Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum. 2008 Jan 15; 59(1):42-50.
Score: 0.057
-
Increased augmentation index in rheumatoid arthritis and its relationship to coronary artery atherosclerosis. J Rheumatol. 2007 Dec; 34(12):2388-94.
Score: 0.057
-
Quantitative measures of rheumatic diseases for clinical research versus standard clinical care: differences, advantages and limitations. Best Pract Res Clin Rheumatol. 2007 Aug; 21(4):601-28.
Score: 0.055
-
Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis. 2007 Dec; 195(2):e135-41.
Score: 0.055
-
QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007 Nov; 66(11):1491-6.
Score: 0.054
-
Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008 Feb; 196(2):756-63.
Score: 0.054
-
Shouldn't standard rheumatology clinical care be evidence-based rather than eminence-based, eloquence-based, or elegance-based? J Rheumatol. 2007 Jan; 34(1):1-4.
Score: 0.053
-
An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol. 2006 Nov; 33(11):2146-52.
Score: 0.052
-
Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther. 2006; 8(6):R186.
Score: 0.050
-
The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum. 2005 Dec; 52(12):3873-9.
Score: 0.049
-
Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005 Oct; 52(10):3045-53.
Score: 0.049
-
Morning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rate. J Rheumatol. 2004 Sep; 31(9):1723-6.
Score: 0.045
-
The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. Arthritis Rheum. 2003 Feb 15; 49(1):59-63.
Score: 0.041